LGLéonie Goeminne

Léonie Goeminne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Léonie Goeminne has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Emmanuel André

    Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium

    5 shared publications
  • Stefan Niemann

    Research Centre Borstel Leibniz Lung Center, Molecular and Experimental Mycobacteriology, Borstel, Germany.

    3 shared publications
  • P. Beckert

    Molecular and Experimental Mycobacteriology Group, Research Centre Borstel, Borstel, Germany; German Centre for Infection Research, Borstel Site, Borstel, Germany

    2 shared publications
  • A. Colmant

    Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium

    1 shared publication
  • Agathe Jouet

    Genoscreen, Lille, France

    1 shared publication
  • Alexandre Colmant

    Service de Microbiologie, Département de Biologie Clinique, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Bruxelles, Belgium

    1 shared publication

Latest Publications

  • Open Access

    Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital

    by Sylvie Goletti, Siméon Zuyten, Léonie Goeminne, Chris Verhofstede, Hector Rodriguez-Villalobos, Monique Bodeus, Peter Stärkel, Yves Horsmans, Benoît Kabamba-Mukadi

    The technique most frequently used to genotype HCV is quantitative RT-PCR. This technique is unable to provide an accurate genotype/subtype for many samples; we decided to develop an in-house method with the goal of accurately identifying the genotype of all samples. As a Belgium National Centre of reference for hepatitis, we developed in-house sequencing not only for 5’UTR and core regions starting from VERSANT LiPA amplicons but also for NS5B regions. The sequencing of VERSANT LiPA amplicons might be useful for many laboratories worldwide using the VERSANT LiPA assay to overcome undetermined results. 100 samples from Hepatitis C virus infected patients analysed by the VERSANT HCV Genotype 2.0 LiPA Assay covering frequent HCV types and subtypes were included in this study. NS5B, 5’UTR and Core home-made sequencing were then performed on these samples. The sequences obtained were compared with the HCV genomic BLAST bank. All the samples were characterised by the VERSANT LiPA assay (8 G1a, 17 G1b, 6 G2, 11 G3, 13 G4, and 10 G6). It was not possible to discriminate between G6 and G1 by the VERSANT LiPA assay for 8 samples and 27 had an undetermined genotype. Forty-one samples were sequenced for the three regions: NS5B, 5’UTR and Core. Twenty-three samples were sequenced for two regions: 5′ UTR and Core and 36 samples were sequenced only for NS5B. Of the 100 samples included, 64 samples were analysed for 5’UTR and Core sequencing and 79 samples were analysed for NS5B sequencing. The global agreement between VERSANT LiPA assay and sequencing was greater than 95%. In this study, we describe a new, original method to confirm HCV genotypes of samples not discriminated by a commercial assay, using amplicons already obtained by the screening method, here the VERSANT LiPA assay. This method thus saves one step if a confirmation assay is needed and might be of usefulness for many laboratories worldwide performing VERSANT LiPA assay in particular.


  • Open Access

    First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium

    by Géraldine Dessilly, Léonie Goeminne, Anne-Thérèse Vandenbroucke, François E Dufrasne, Anandi Martin, Benoît Kabamba-Mukadi

    The WHO urges action against the threat posed by HIV drug resistance. It is well known that the sensitivity of Next-Generation Sequencing (NGS) is greater than that of Sanger Sequencing (SS). The objective of this study was to evaluate the performance of the novel NGS HIV-1 drug resistance monitoring system. NGS analyses were performed on 67 plasma samples from HIV-1 infected patients using the Sentosa SQ HIV Genotyping Assay from Vela-Dx. This kit was used on a semi-automated Ion Torrent-based platform. Sequences were compared to those obtained by SS. Samples were analysed in the same and in separate runs. Quality controls (QC) were added to control sequencing processes of protease (PRO), reverse transcriptase (RT) and integrase (INT) regions. Of the 41 analysed samples, 33 (80.5%) had identical drug resistance interpretation reports. Discrepant results were observed for eight samples. Five of them were only detected by NGS and had drug resistance mutations (DRMs) with an allelic frequency below the limit of detection of the SS method (between 6.3 to 20.5%). Two DRMs were only identified using the SS method. The sequences were similar in 98.2% of cases (counting variants as mismatches) and homologous in 99.9% if missed variants. Duplicated samples in a single run were similar in 95.7% (99.9%) of cases. Duplicated samples in two different runs were 98% (100%) homologous. QC results were manually assessed with a score of 340/340 for detection of DRMs in PRO and RT and 100% for INT sequencing. This is the first preliminary evaluation in Belgium employing the Sentosa SQ HIV Genotyping Assay. The NGS appears to be a promising tool for the detection of DRMs in HIV-1 patients and showed a higher sensitivity compared to SS. Large studies assessing the clinical relevance of low frequency DRMs are needed.


  • Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study

    by Ndivhuho A Makhado, Edith Matabane, Mauro Faccin, Claire Pinçon, Agathe Jouet, Fairouz Boutachkourt, Léonie Goeminne, Cyril Gaudin, Gugu Maphalala, Patrick Beckert, et al.


  • Open Access

    Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results

    by Kamela Charmaine Ng, Conor Joseph Meehan, Gabriela Torrea, Léonie Goeminne, Maren Diels, Leen Rigouts, Bouke Catherine de Jong, Emmanuel André

    Clinical informatics, decision support for health professionals, electronic health records, and ehealth infrastructures.


  • Open Access

    Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria

    by E. Andre, L. Goeminne, A. Cabibbe, P. Beckert, B. Kabamba Mukadi, V. Mathys, S. Gagneux, S. Niemann, J. Van Ingen, E. Cambau


  • Open Access

    Immune reconstitution inflammatory syndrome due to Mycobacterium genavense in an HIV-infected patient: Impact of rapid species identification by rpoB sequencing on clinical management

    by Emmanuel Andre, Leila Belkhir, Léonie Goeminne, Alexandre Colmant, Jean-Yves Sottiaux, Halil Yildiz, Jean Ruelle, Michel Delmee, Bernard Vandercam, Jean-Philippe Defour

    Introduction: Diagnosis of infections due to Mycobacterium tuberculosis has been recently facilitated with the worldwide implementation of rapid molecular tests. However, the diagnosis of non-TB mycobacteria (NTM) remains a major challenge for laboratories, as this group of bacteria contains over 150 different species with highly variable bacteriological properties. The development and implementation in clinical practice of techniques allowing rapid identification of NTM at the species level is, therefore, important for clinical laboratories. We report the case of an HIV-1 positive patient presenting with severe NTM infection who benefited from a novel rapid diagnostic technique, based on the direct sequencing of the rpoB gene from smear-positive clinical samples. Case Presentation: A 43-year-old HIV-1 positive woman was hospitalized for bicytopenia in the presence of an inflamed supraclavicular lymph node. The diagnosis of disseminated Mycobacterium genavense infection, which involved the bone marrow and several lymph nodes, was missed by conventional mycobacteriological techniques. Identification was obtained by performing direct sequencing of the rpoB gene. Conclusion: We describe a novel technique that allows the rapid diagnosis of NTM infections directly from biological samples. This technique is now implemented in our routine workflow for smear and culture-positive samples, after the exclusion of TB, by rapid molecular assays.


  • Open Access

    Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease

    by Ilie‐Cosmin Stancu, Laurence Ris, Bruno Vasconcelos, Claudia Marinangeli, Léonie Goeminne, Vincent Laporte, Laetitia E. Haylani, Julien Couturier, Olivier Schakman, Philippe Gailly, et al.

    Tau alterations are now considered an executor of neuronal demise and cognitive dysfunction in Alzheimer's disease (AD). Mouse models combining amyloidosis and tauopathy and their parental counterparts are important tools to further investigate the interplay of abnormal amyloid‐β (Aβ) and Tau species in pathogenesis, synaptic and neuronal dysfunction, and cognitive decline. Here, we crossed APP/PS1 mice with 5 early‐onset familial AD mutations (5xFAD) and TauP301S (PS19) transgenic mice, denoted F + /T + mice, and phenotypically compared them to their respective parental strains, denoted F + /T – and F – /T + respectively, as controls. We found dramatically aggravated tauopathy (~10‐fold) in F + /T + mice compared to the parental F – /T + mice. In contrast, amyloidosis was unaltered compared to the parental F + /T – mice. Tauopathy was invariably and very robustly aggravated in hippocampal and cortical brain regions. Most important, F + /T + displayed aggravated cognitive deficits in a hippocampus‐dependent spatial navigation task, compared to the parental F + /T – strain, while parental F – /T + mice did not display cognitive impairment. Basal synaptic transmission was impaired in F + /T + mice compared to nontransgenic mice and the parental strains (≥40%). Finally, F + /T + mice displayed a significant hippocampal atrophy (~20%) compared to nontransgenic mice, in contrast to the parental strains. Our data indicate for the first time that pathological Aβ species (or APP/PS1) induced changes in Tau contribute to cognitive deficits correlating with synaptic deficits and hippocampal atrophy in an AD model. Our data lend support to the amyloid cascade hypothesis with a role of pathological Aβ species as initiator and pathological Tau species as executor.—Stancu, I.‐C., Ris, L., Vasconcelos, B., Marinangeli, C., Goeminne, L., Laporte, V., Haylani, L. E., Couturier, J., Schakman, O., Gailly, P., Pierrot, N., Kienlen‐Campard, P., Octave, J.‐N., Dewachter, I. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease. FASEB J . 28, 2620–2631 (2014). www.fasebj.org